FITC Anti-Chlamydia trachomatis MOMP antibody (ab30951)
Key features and details
- FITC Goat polyclonal to Chlamydia trachomatis MOMP
- Suitable for: IHC-P, ICC/IF
- Reacts with: Chlamydia trachomatis
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
Overview
-
Product name
FITC Anti-Chlamydia trachomatis MOMP antibody
See all Chlamydia trachomatis MOMP primary antibodies -
Description
FITC Goat polyclonal to Chlamydia trachomatis MOMP -
Host species
Goat -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
ab30951 recognises Major Outer Membrane Protein of Chlamydia trachomatis. -
Tested applications
Suitable for: IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Chlamydia trachomatis -
Immunogen
Full length protein: Chlamydia trachomatis, Major Outer Membrane Protein
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.20
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading...
-
Purification notes
ab30951 was chromatographically purified. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab30951 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
Use at an assay dependent concentration.
|
|
ICC/IF |
1/20 - 1/100.
|
Notes |
---|
IHC-P
Use at an assay dependent concentration. |
ICC/IF
1/20 - 1/100. |
Target
-
Relevance
Chlamydia is caused by the bacterium Chlamydia trachomatis. The intracytoplasmic inclusions caused by the bacterium are draped around the infected cell's nucleus. Chlamydia trachomatis is an intracellular organism that has a genome size of approximately 500-1000 kilobases and contains both RNA and DNA. The organism is also extremely temperature sensitive and must be refrigerated at 4°C as soon as a sample is obtained. Colonization of Chlamydia begins with attachment to sialic acid receptors on the eye, throat or genitalia. It persists at body sites that are inaccessible to phagocytes, T cells, and B cells. It also exists as 15 different serotypes. These serotypes cause four major diseases in humans: endemic trachoma (caused by serotypes A and C), sexually transmitted disease and inclusion conjunctivitis (caused by serotypes D and K), and lymphogranuloma venereum (caused by serotypes L1, L2, and L3). Studies reveal that Chlamydia, because of its cell wall, is able to inhibit phagolysosome fusion in phagocytes. The cell wall is proposed to be Gram negative in that it contains an outer lipopolysaccharide membrane, but it lacks peptidoglycan in its cell wall. This lack of peptidoglycan is shown by the inability to detect muramic acid and antibodies directed against it. It may, however, contain a carboxylated sugar other than muramic acid. The proposed structure consists of a major outer membrane protein cross linked with disulfide bonds. It also contains cysteine rich proteins (CRP) that may be the functional equivalent to peptidoglycan. This unique structure allows for intracellular division and extracellular survival (Hatch 1996). Chlamydia usually infects the cervix and fallopian tubes of women and the urethra of men. Chlamydial infections are believed to be one of the most common of all STDs. It is generally thought that in a population of 15 million, there are up to 300,000 cases of chlamydia each year. Thus, there are many undiagnosed cases of chlamydia in the community. It has been estimated that the true prevalence of chlamydia in the sexually active population may be in the order of 5% to 10%. Chlamydia is one of the leading causes of blindness in underdeveloped countries. -
Cellular localization
Outer membrane; multi pass membrane protein. -
Database links
- Entrez Gene: 3688076 Chlamydia trachomatis
- Entrez Gene: 884473 Chlamydia trachomatis
- SwissProt: P06597 Chlamydia trachomatis
- SwissProt: P08780 Chlamydia trachomatis
- SwissProt: P13467 Chlamydia trachomatis
- SwissProt: P16155 Chlamydia trachomatis
- SwissProt: P17451 Chlamydia trachomatis
- SwissProt: P19542 Chlamydia trachomatis
see all -
Alternative names
- Major Outer Membrane Protein antibody
- MOMP antibody
- omp1 antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab30951 has been referenced in 3 publications.
- Huang X et al. Integrating lncRNAs and mRNAs Expression Profiles in Penicillin-Induced Persistent Chlamydial Infection in HeLa Cells. Front Mol Biosci 9:744901 (2022). PubMed: 35252346
- Huang X et al. Akt Phosphorylation Influences Persistent Chlamydial Infection and Chlamydia-Induced Golgi Fragmentation Without Involving Rab14. Front Cell Infect Microbiol 11:675890 (2021). PubMed: 34169005
- Derrick T et al. Inverse relationship between microRNA-155 and -184 expression with increasing conjunctival inflammation during ocular Chlamydia trachomatis infection. BMC Infect Dis 16:60 (2016). PubMed: 26842862